Award recordCONTRACT

BIOCRYST PHARMACEUTICALS INC

PIID 36C26024F0270· VHA· 260-NETWORK CONTRACT OFFICE 20 (36C260)· 6505 · DRUGS AND BIOLOGICALS· FY2024· $357,245 net obligations· UEI MGXADJ6SCLJ5· NC

Description

BULK ORDER ORLADEYO - 2025 PRICE INCREASE FOR QTY. 3 OUT OF 13.

Base award description: BULK ORDER ORLADEYO

First action · last action
2024-03-12 · 2026-02-12
Transactions
3
First transaction's obligation
$385,448
Base + all options value (sum of deltas)
$357,245
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
—
Offers received
1
SDVOSB flag on record
No
Parent IDV
36F79721D0166
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING

Modification chain · 3 transactions

Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.

$387,619$0Base award · 2024-03-12 · this action $385,448 · running total $385,448Modification P00001 · 2025-02-04 · this action $2,170 · running total $387,619Modification P00002 · 2026-02-12 · this action -$30,373 · running total $357,245
  • Base2024-03-12+$385,448= $385,448
  • Mod P000012025-02-04+$2,170= $387,619
  • Mod P000022026-02-12-$30,373= $357,245
TransactionAction dateThis action (delta)Running totalDescription on this transaction
Base2024-03-12+$385,448$385,448BULK ORDER ORLADEYO
Mod P00001· FUNDING ONLY ACTION2025-02-04+$2,170$387,619BULK ORDER ORLADEYO - 2025 PRICE INCREASE FOR QTY. 3 OUT OF 13.
Mod P00002· OTHER ADMINISTRATIVE ACTION2026-02-12−$30,373$357,245BULK ORDER ORLADEYO - 2025 PRICE INCREASE FOR QTY. 3 OUT OF 13.

Related awards · 11

Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.

Other VA awards to the same recipient (UEI MGXADJ6SCLJ5)

AwardOffice · PSC / listingNet obligationsFY
36E79726A0015NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2026
36C24926F0152249-NETWORK CONTRACT OFFICE 9 (36C249) · 6505 · DRUGS AND BIOLOGICALS$30,293FY2026
36C26026F0294260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS$151,465FY2026
36C26026F0006260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS$360,000FY2026
36C26025F0296260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS$29,408FY2025
36C26025F0070260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS$242,987FY2025

Other recipients under 6505 from 260-NETWORK CONTRACT OFFICE 20 (36C260) (most recent first)

AwardRecipientOfficeNet obligationsFY
36C26026F0379COSETTE PHARMACEUTICALS, INC.260-NETWORK CONTRACT OFFICE 20 (36C260)$3,466FY2026
36C26026P0671MCKESSON PLASMA AND BIOLOGICS LLC260-NETWORK CONTRACT OFFICE 20 (36C260)$18,262FY2026
36C26026F0349AGIOS PHARMACEUTICALS, INC.260-NETWORK CONTRACT OFFICE 20 (36C260)$73,080FY2026
36C26026F0306BRACCO DIAGNOSTICS INC.260-NETWORK CONTRACT OFFICE 20 (36C260)$337,422FY2026
36C26026F0298PROGENICS PHARMACEUTICALS INC260-NETWORK CONTRACT OFFICE 20 (36C260)$469,134FY2026

Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C26024F0270_3600_36F79721D0166_3600 · retrieved 2026-09-26.